Genetic Signatures (ASX:GSS) YoY EBITDA Growth: 46.03% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genetic Signatures YoY EBITDA Growth?

Genetic Signatures ASX:GSS +1.72% YoY EBITDA Growth is 46.03% as of Dec. 2025. The stock has 4 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Genetic Signatures's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was 46.03%.

Genetic Signatures's EBITDA per Share for the six months ended in Dec. 2025 was A$-0.03.

Genetic Signatures YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Genetic Signatures's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Signatures YoY EBITDA Growth Chart

Genetic Signatures Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 344.44 45.45 -365.63 -44.71 42.28

Genetic Signatures Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -88.10 -11.63 20.25 81.25 46.03

Genetic Signatures YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Genetic Signatures's YoY EBITDA Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (A: Jun. 2025 )
=(EBITDA per Share (A: Jun. 2025 )-EBITDA per Share (A: Jun. 2024 ))/ | EBITDA per Share (A: Jun. 2024 ) |
=(-0.071--0.123)/ | -0.123 |
=42.28 %

Genetic Signatures's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(-0.034--0.063)/ | -0.063 |
=46.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 46.03% mean?
Genetic Signatures (ASX:GSS) has a YoY EBITDA Growth of 46.03% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Genetic Signatures and its competitors.
Is Genetic Signatures' YoY EBITDA Growth too high?
Genetic Signatures' current YoY EBITDA Growth is 46.03%.
How does Genetic Signatures' YoY EBITDA Growth compare to TMO and DHR?
Genetic Signatures' YoY EBITDA Growth of 46.03% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Diagnostics & Research company?
A good YoY EBITDA Growth depends on the Medical Diagnostics & Research industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Genetic Signatures and its competitors. Genetic Signatures's current YoY EBITDA Growth is 46.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Signatures stock overvalued right now?
Based on GuruFocus' analysis, Genetic Signatures (ASX:GSS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.39, compared to a current price of A$0.06 — trading 84.9% below its estimated fair value. The current YoY EBITDA Growth is 46.03%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Genetic Signatures (ASX:GSS), the current YoY EBITDA Growth is 46.03% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Signatures Business Description

Address 7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042
Genetic Signatures Ltd is a specialist molecular diagnostics company, specializing in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are based in Australia, with sales and support teams in the UK, Germany, and the United States.